Prostate biopsy with fusion imaging of magnetic resonance imaging and transrectal ultrasound

Prostate biopsy with fusion imaging of magnetic resonance imaging and transrectal ultrasound - Prostate biopsy with fusion imaging of magnetic resonance imaging and transrectal ultrasound

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029102

Enrollment

Registered

2017-09-12

Start date

2017-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urology

Interventions

BioJet system

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: ?Serum PSA level: 4.0-20.0ng/ml ?Localized prostate cancer was suspected ?Significant cancer was suspected by MRI ?To obtain consent

Exclusion criteria

Exclusion criteria: ?Anal stenosis ?Diabetes ?Infection nest in perineum site ?Clear hypoechoic area was detected by US on cancer suspecting region

Design outcomes

Primary

Measure	Time frame
We evaluate the number of adverse events, hematuria, prostatitis and cancer detection rate of transperineal targeted prostate biopsy with BioJet system compared to systematic biopsy.	—

Countries

Japan

Contacts

Public ContactIppei Chikazawa

Kanazawa Medical University Department of Urology

i-chika@kanazawa-med.ac.jp076-286-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026